Skip to main navigation
Skip to search
Skip to main content
Albert Einstein College of Medicine Home
Home
Faculty
Departments
Grants
Publications
Prizes
Search by expertise, name or affiliation
Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?
Romàn Pérez-Soler
Medicine
Research output
:
Contribution to journal
›
Review article
›
peer-review
175
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Exanthema
100%
ErbB Receptors
95%
Erlotinib Hydrochloride
48%
Head and Neck Neoplasms
30%
Non-Small Cell Lung Carcinoma
20%
Cetuximab
19%
Gefitinib
19%
Survival
17%
Ovarian Neoplasms
14%
Maximum Tolerated Dose
9%
Survival Rate
5%
Clinical Trials
5%
Neoplasms
4%
Therapeutics
2%